05 September 2018
The updated study analyses events, prospects and sales opportunities shaping the development, production and marketing of drugs for the treatment of psoriasis. The analysis shows multilevel revenue forecasting and qualitative assessments. The work also explores activities of leading companies providing those medicines, assessing their potentials from 2016.
In 2015 biological drugs formed dominant source of revenue for manufacturers, accounting for 78.5% of the global drug market for psoriasis. However that segment will decline in market share over the forecast period as leading products such as AbbVie’s Humira (adalimumab), Amgen/Pfizer’s Enbrel (etanercept) and J&J/Merck’s Remicade (infliximab) face strong competition from lower-cost biosimilars and new biologics.
Alastair McDougall, a pharmaceutical industry analyst in visiongain, said: “The psoriasis drugs market is dynamic, with a lot of new products reaching the marketplace in the next few years. Many of the current biologics are coming off-patent, new biologics with novel mechanisms of action are being launched, and a lot of companies are actively developing biosimilars. Competition in the biologics sector will be fierce, and efficacy, safety and price will all be key considerations when evaluating products.”
Visiongain’s investigation shows revenue predictions at overall world market, submarket, product and national level. The report’s overarching analysis gives revenue forecasts to 2026 for three submarkets at world level:
• Systemic small molecule treatments
• Topical therapies.
The study also forecasts revenues of established brands and medicines expected from 2016. That work assesses 13 drugs to 2026, including these brands:
• Humira (adalimumab)
• Enbrel (etanercept)
• Remicade (infliximab)
• Stelara (ustekinumab)
• Otezla (apremilast)
• Cosentyx (secukinumab).
The analysis also covers prominent national markets for psoriasis drug sales, with revenue forecasts to 2026 for these 11 countries:
• Germany, France, Italy, Spain and UK (the EU5 group)
• Brazil, Russia, India and China (BRIC countries).
Visiongain’s survey examines leading pharmaceutical companies in that market. That work discusses mergers and acquisitions, collaborations and R&D for organisations including AbbVie, Amgen, Johnson & Johnson, Pfizer, Celgene, LEO Pharma and Novartis.
Psoriasis Drugs Market Forecasts 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth